Clinical and economic outcomes associated with sequential treatment in patients with advanced renal cell carcinoma (aRCC).

4566Background: Immuno-oncology therapies (IOs) and tyrosine kinase inhibitors (TKIs) are recommended for the treatment of aRCC. As new drugs and combination regimens emerge, there is interest in g...